Vol. 17/No. 14 | Oncology Live®

July 07, 2016

Antoni Ribas, MD, PhD, whose work has helped guide and define the growing array of anticancer immunotherapy drugs, was honored in the Melanoma category with a 2015 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

July 07, 2016

Geoffrey R. Oxnard, MD, discusses the potential for BRAF-targeting therapies in non-small cell lung cancer.

July 06, 2016

Experts identify practice-changing or noteworthy abstracts in their field from the research presented at the 2016 ASCO Annual Meeting.

July 06, 2016

The types of BRAF mutations in non-small cell lung cancer may differ from those observed in melanoma, and a greater understanding of these nuances and their sensitivity to currently available drugs is a central focus of ongoing research.

July 05, 2016

Even as our understanding of the biology of prostate and bladder cancers improves and treatment protocols are refined, there remain many clinical scenarios in which no clear-cut answers are available.

July 05, 2016

Suzanne L. Topalian, MD, discusses progress in PD-1/PD-L1 immunotherapies and the prospects for developing biomarkers to better identify patients who would benefit from the new agents.

July 04, 2016

An ongoing phase II, four-cohort trial involving capmatinib (INC280), an oral MET inhibitor, will determine the clinical activity of the agent in pretreated patients with advanced non-small cell lung cancer who have undergone one or two lines of therapy.

July 03, 2016

The importance of gaining the input of individual patients with cancer into their own medical management cannot be overstated.

June 30, 2016

The field of cancer biology is entering a postgenomic era in which most types of human cancer will have been extensively sequenced through efforts such as The Cancer Genome Atlas and the International Cancer Genome Consortium.